Amphastar Pharmaceuticals (AMPH) Interest Expenses (2013 - 2026)

Amphastar Pharmaceuticals' Interest Expenses history runs 14 years deep, the most recent figure standing at $7.3 million for Q1 2026.

• On a quarterly basis, Interest Expenses fell 3.79% year-over-year to $7.3 million in Q1 2026; TTM through Mar 2026 was $24.4 million, a 28.57% increase from a year earlier, with the FY2025 full-year figure at $407.9 million, up 328.13% from the prior year.
• Interest Expenses improved to $7.3 million in Q1 2026 per AMPH's latest filing, from $6.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $482.0 million in Q2 2023 and bottomed at -$129000.0 in Q4 2023.
• The 5-year median for Interest Expenses is $8.6 million (2024), against an average of $92.4 million.
• Across the five-year window, Interest Expenses plunged 107.38% in 2023 and jumped 2342.64% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $1.7 million in 2022, then slumped by 107.38% to -$129000.0 in 2023, then soared by 2342.64% to $2.9 million in 2024, then surged by 129.17% to $6.6 million in 2025, then grew by 10.03% to $7.3 million in 2026.
• Per Business Quant, the three latest AMPH Interest Expenses figures stand at $7.3 million (Q1 2026), $6.6 million (Q4 2025), and $33.3 million (Q3 2025).